DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells.
作者： K. Masur , F Schwartz , F. Entschladen , B. Niggemann , K.S. Zaenker
DOI: 10.1016/J.REGPEP.2006.07.003
关键词:
摘要: Abstract Background The glucagon-like peptides-1 and -2 (GLP-1 -2) are co-secreted after food intake from intestinal L cells. Since both peptides rapidly degraded by dipeptidyl peptidase-IV (DPPIV), research is focused on the development of DPPIV inhibitors or resistant. Aims In this study we investigated, whether inhibition activity resulting increased half-life substrates may influence cancer progression. Methods We examined proliferation migratory two human colon cell lines (SW480, HT29) stimulation with GLP-2 in combination without inhibitors. Results Migratory was 25% 20% matrix induced to a maximum 45% (100 nM GLP-2). cells expressing CD26, migration prolonged addition concentration dependent manner. After treatment doubling time decreased 2.4 1.5 days — enhanced effect GLP-2. Conclusions use together led as well elevated activity. Therefore, could increase risk promoting an already existing tumour support potential metastasize.
elsevier.com
sci-hub.se 参考文章(44)
Jasleen Jasleen, Stanley W. Ashley, Naoshi Shimoda, Michael J. Zinner, Edward E. Whang, Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Digestive Diseases and Sciences. ,vol. 47, pp. 1135- 1140 ,(2002) , 10.1023/A:1015062712767
Esther Velázquez, Juan M. Ruiz-Albusac, Enrique Blázquez, Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. FEBS Journal. ,vol. 270, pp. 3001- 3009 ,(2003) , 10.1046/J.1432-1033.2003.03677.X
Ernest Y. Tan, Michelle Mujoomdar, Jonathan Blay, Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior. American Journal of Pathology. ,vol. 165, pp. 319- 330 ,(2004) , 10.1016/S0002-9440(10)63299-3
Bernardo Yusta, Daniel J. Drucker, Robin P. Boushey, Glucagon-like Peptide (GLP)-2 Reduces Chemotherapy-associated Mortality and Enhances Cell Survival in Cells Expressing a Transfected GLP-2 Receptor Cancer Research. ,vol. 61, pp. 687- 693 ,(2001)
Kurt S. Zanker, Bernd Niggemann, Frank Entschladen, Kai Masur, Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Research. ,vol. 61, pp. 2866- 2869 ,(2001)
Cameron E. McCoy, William B. McCombs, James C. Stinson, Kenneth C. Mazur, Nancy D. Mabry, Albert Leibovitz, Classification of human colorectal adenocarcinoma cell lines. Cancer Research. ,vol. 36, pp. 4562- 4569 ,(1976)
Daniel J. Drucker, Glucagon-like peptide 2. The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 1759- 1764 ,(2001) , 10.1210/JCEM.86.4.7386
Carolyn F. Deacon, What do we know about the secretion and degradation of incretin hormones Regulatory Peptides. ,vol. 128, pp. 117- 124 ,(2005) , 10.1016/J.REGPEP.2004.06.007
MA Benjamin, DM McKay, PC Yang, H Cameron, MH Perdue, Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse Gut. ,vol. 47, pp. 112- 119 ,(2000) , 10.1136/GUT.47.1.112
K Bulut, J.J Meier, N Ansorge, P Felderbauer, F Schmitz, P Hoffmann, W.E Schmidt, B Gallwitz, Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro—evidence for a TGF-β-mediated effect Regulatory Peptides. ,vol. 121, pp. 137- 143 ,(2004) , 10.1016/J.REGPEP.2004.04.014